李劍，主任醫(yī)師，博士生導師。2001年畢業(yè)于北京協(xié)和醫(yī)院，后長期在協(xié)和醫(yī)院內(nèi)科/血液內(nèi)科工作。目前為血液內(nèi)科科室主任。擔任中華醫(yī)學會血液學分會常委，北京醫(yī)學會血液學分會副主委等。

長期從事漿細胞疾病和血液罕見病的研究；構建了全球最大的POEMS綜合征臨床隊列，首次提出POEMS綜合征的預后分層系統(tǒng)，構建了POEMS綜合征的診療體系。優(yōu)化并完善了輕鏈型淀粉樣變的治療模式；多學科合作開創(chuàng)了輕鏈型淀粉樣變的多影像組學技術；探索了有中國特色的Castleman病的臨床分型及治療路徑；相關成果被寫入國內(nèi)外指南和教材。承擔10余項國家和省部級科研課題，在Blood等雜志發(fā)表論文80余篇。培養(yǎng)博士、碩士、博士后20余名。

午夜92福利1000,午夜92福利1000,久久国产亚洲高清观看5388,美女不拍网站免费观看,欧美***天天久久综合精品,中文字幕日韩系列中文字幕,综合久久国产九一剧情麻豆,丰满人妻在线免费视频,奶子大逼又嫩操起来真爽

1.Xuezhu Wang#, Kaini Shen#, Yuke Zhang, Yajuan Gao, Bowei Liu, Yubo Guo, Chao Ren, Zhenghai Huang, Xiao Li, Long Chang, Haiyan Ding, Hui Zhang, PHD, Zhuang Tian, Marcus Hacker, Shuyang Zhang, Yining Wang, Jian Li*, Xiang Li*, Li Huo. Molecular Stratification of Light-Chain Cardiac Amyloidosis with 18F-Florbetapir and 68Ga-FAPI-04 for Enhanced Prognostic Precision. JACC: Cardiovascular Imaging. 2025; 18:323-336.

2.Xuezhu Wang#, Liping Zuo#, Yanying Yu#, Xinyi Xiong, Jian Xu, Bing Qiao, Jia Chen, Hao Cai, Qi Yan, Hongxiao Han, Xin-xin Cao, Jun Deng, Chunyan Sun*, Jian Li*. Clonal Hematopoietic Mutations in Plasma Cell Disorders: Clinical Subgroups and Shared Pathogenesis. Genomics, Proteomics & Bioinformatics. 2025; 23:qzaf027.

3.Kaini Shen#, Zhuang Tian#, Yajuan Gao#, Yining Wang, Li Huo, Jian Li*, Yun Zhang*, Shuyang Zhang*; On behalf of Chinese Society of Rare Diseases and Rare Diseases Branch of China Research Hospital Association. Chinese consensus on the diagnosis and treatment of immunoglobulin light-chain cardiac amyloidosis. Chinese Medical Journal. 2024; 137:127-29.

4.Lu Zhang,# Qin-hua Liu,# Hui Zhou#, Hui-lai Zhang, Yu-jun Dong, Xiao-bo Wang, Lu-qun Wang, Li-ping Su, Xiao-jing Yan, Yan Li, Ming-zhi Zhang, Kai-yang Ding, Hui-han Wang, Hong-ling Peng, Li-ye Zhong, Lin Yang, Lin-tao Bi, Da Gao, Guang-xun Gao, Liang Huang, Chun-yan Sun, Jia Song, Wen-bin Qian, Wen-rong Huang, Zhen-ling Li, Yao Liu, Jian Li*. Asymptomatic multicentric Castleman disease: A potential early stage of idiopathic MCD. Blood Advances. 2024; 8:5598-602.

5.Lu Zhang#, Yu-jun Dong#, Hong-ling Peng#, Hao Li, Ming-zhi Zhang, Hui-han Wang, Qin-hua Liu, Li-ping Su, Li-ye Zhong, Wen-jun Wu, Liang Huang, Xiao-jing Yan, Lei Fan, Wen-jiao Tang, Zhen-ling Li, Lin-tao Bi, Yan Li, Guang-xun Gao, Li Gao, Ting-bo Liu, Yong-qiang Wei, Yao Liu, Li Yu, Hui Zhou, Chun-yan Sun, Wen-bin Qian, De-hui Zou, Hui-lai Zhang, Kai-yang Ding, Xiao-bo Wang, Ou Bai, Wen-rong Huang, Bing Chen, Lin Yang, Jia Song, Da Gao, Tong Chen, Jun Luo, Shu-ye Wang, Liang-ming Ma, David C. Fajgenbaum, Jian Li*. A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria. The Lancet Regional Health - Western Pacific. 2023; 34:100720.

6.Jiamin Zhou#, Lu Zhang#, Xueqing Liu, Miaoyan Zhang, Jian Li*, Weihong Zhang*. The evolution of pulmonary involvement in idiopathic multicentric Castleman disease-not otherwise specified: From nodules to cysts or consolidation. Chest 2023; 164(2):418-28.

7.Xuezhu Wang#, Yubo Guo#, Yajuan Gao#, Chao Ren, Zhenghai Huang, Bowei Liu, Xiao Li, Long Chang, Kaini Shen, Haiyan Ding, DeHui Zhang, Zhuang Tian, Marcus Hacker, Shuyang Zhang, Yining Wang, Jian Li*, Xiang Li*, Li Huo*. Feasibility of 68Ga-Labeled Fibroblast Activation Protein Inhibitor Positron Emission Tomography/Computed Tomography in Light-Chain Cardiac Amyloidosis. JACC: Cardiovascular Imaging 2022; 15(11):1960-70.

8.Kai-ni Shen#, Wei-jun Fu#, Yu Wu#, Yu-jun Dong, Zhong-xia Huang, Yong-qiang Wei, Chun-rui Li, Chun-yan Sun, Ye Chen , Hui-lei Miao, Yue-lun Zhang, Xin-xin Cao, Dao-bin Zhou, and Jian Li*. Doxycycline combined with bortezomib-cyclophosphamide-dexamethasone chemotherapy for newly diagnosed cardiac light-chain amyloidosis: a multicenter randomized controlled trial. Circulation 2022; 145(1):8-1. (R)

9.Lu zhang, Ai-lin Zhao, Ming-hui Duan, Zhiyuan Li, Xinxin Cao, Jun Feng, Daobin Zhou, Dingrong Zhong, David FC, Jian Li*. Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic Multicentric Castleman disease. Blood 2019; 133(16):1720-28. (R)